The political news this week in the UK is full of Prime Minister Rishi Sunak’s deal with the European, commented Ropes & Gray private equity counsel David Dowling.
The so-called 'Windsor Framework' sets out the terms on which goods can move freely between mainland UK and Northern Ireland, while ensuring continuity on the island of Ireland.
Although not the primary focus of the talks, an additional benefit may be that it reverses some of the damage that many in the scientific community feel was done to the sector by Brexit, according to Mr Dowling. As part of the UK’s separation from the EU, UK researchers lost access to ‘Horizon Europe’, a pot of funding and the ability to collaborate across Europe. These collaborations are likely to be particularly important in 2023, as biotechs try to navigate downward pressure on fundraising rounds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze